Status:

UNKNOWN

Intervention to REduce anticholinerGic burdEN in oldER pATiEnts (REGENERATE) Aged 65 Years and Older

Lead Sponsor:

University of Aberdeen

Conditions:

Anticholinergic Adverse Reaction

Eligibility:

All Genders

65-100 years

Phase:

NA

Brief Summary

Medications with anticholinergic properties are frequently prescribed for several conditions in older age; for example cardiovascular drugs (e.g. digoxin, furosemide), urologicals (e.g. darifenacin, o...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for stopping and/or switching medications
  • Patients who are:
  • aged 65 and over
  • able to provide informed consent.
  • on one or more long-term drugs (have been prescribed a minimum 6 weeks) with ACB potential (Anticholinergic Cognitive Burden scale ≥3) (defined according to Boustani et al (Boustani, Campbell et al. 2008)
  • Exclusion Criteria for stopping and/or switching medications
  • Patients who:
  • are without capacity to provide informed consent.
  • have severe mental illness \[such as diagnosis of severe anxiety, severe depression, severe dementia etc.\].
  • are terminally ill (life expectancy less than 6 months).
  • in opinion of responsible clinician are not suitable.
  • are taking part in another study.
  • Health care professional inclusion criteria for interviews
  • \- Professionals: doctors (consultants, GPs), pharmacist in primary and secondary care involved in the care of patients aged 65 and over on polypharmacy regimes/likely to have anticholinergic burden and have taken part in the study by delivering the intervention
  • Patients inclusion criteria for interviews
  • \- Patients: patients aged 65 years and over who met eligible criteria and have taken part in the REGENERATE study will be selected.
  • Exclusion criteria for interviews
  • \- Participants who cannot understand English fluently

Exclusion

    Key Trial Info

    Start Date :

    July 17 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 28 2022

    Estimated Enrollment :

    40 Patients enrolled

    Trial Details

    Trial ID

    NCT04660838

    Start Date

    July 17 2021

    End Date

    February 28 2022

    Last Update

    September 14 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Peterculter Medical Practice

    Aberdeen, United Kingdom, AB14 0RP